IL1B and COVID-19: Additionally, there have been hypotheses proposing that SARS-CoV-2-related diarrhoea and gastrointestinal dysfunction in COVID-19 patients may involve activation of the ENS and EGCs, as activated EGCs are known to release IL-1 and other inflammatory mediators typically observed in COVID-19 patients (106, 116–119).